Company Filing History:
Years Active: 2019-2024
Title: Hélène Sicard: Innovator in Cancer Treatment
Introduction
Hélène Sicard is a prominent inventor based in Marseilles, France. She has made significant contributions to the field of cancer treatment, particularly in the area of peripheral T cell lymphoma. With a total of six patents to her name, her work is recognized for its innovative approaches to medical challenges.
Latest Patents
Hélène Sicard's latest patents include a compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma. This invention relates to methods for the treatment, prevention, and diagnosis of this type of lymphoma using compounds that specifically bind KIR3DL2. Additionally, she has developed methods for the treatment of peripheral T cell lymphoma using compounds that bind NKp46. These compounds are designed to deplete tumor cells expressing NKp46 on their surface, and her work also encompasses the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays.
Career Highlights
Hélène Sicard is currently associated with Innate Pharma, where she continues to advance her research and innovations. Her career is marked by a commitment to improving therapeutic options for patients suffering from cancer.
Collaborations
Some of her notable coworkers include Laurent Gauthier and Benjamin Rossi, who contribute to her research endeavors and collaborative projects.
Conclusion
Hélène Sicard's work exemplifies the impact of innovative thinking in the medical field, particularly in the treatment of peripheral T cell lymphoma. Her contributions through patents and research continue to pave the way for advancements in cancer therapy.